Oliver Luxxe Assets LLC Raises Stake in Encompass Health Co. (NYSE:EHC)

Oliver Luxxe Assets LLC lifted its stake in shares of Encompass Health Co. (NYSE:EHC) by 4.8% during the 4th quarter, Holdings Channel reports. The fund owned 63,453 shares of the company’s stock after buying an additional 2,900 shares during the quarter. Encompass Health comprises 1.0% of Oliver Luxxe Assets LLC’s portfolio, making the stock its 26th largest holding. Oliver Luxxe Assets LLC’s holdings in Encompass Health were worth $5,860,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. UMB Bank n.a. raised its stake in Encompass Health by 387.7% during the third quarter. UMB Bank n.a. now owns 317 shares of the company’s stock worth $31,000 after purchasing an additional 252 shares during the period. V Square Quantitative Management LLC increased its holdings in shares of Encompass Health by 53.0% during the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock worth $39,000 after buying an additional 140 shares during the last quarter. Avior Wealth Management LLC purchased a new stake in shares of Encompass Health during the 3rd quarter valued at approximately $40,000. Benjamin F. Edwards & Company Inc. grew its position in Encompass Health by 58.9% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company’s stock worth $46,000 after acquiring an additional 198 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Encompass Health during the second quarter worth $58,000. Institutional investors and hedge funds own 97.25% of the company’s stock.

Encompass Health Stock Up 0.1 %

Shares of EHC traded up $0.10 during midday trading on Monday, hitting $91.28. The company had a trading volume of 361,439 shares, compared to its average volume of 546,428. The company’s 50-day simple moving average is $98.90 and its 200-day simple moving average is $93.53. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.04 and a current ratio of 1.04. Encompass Health Co. has a 1 year low of $67.12 and a 1 year high of $104.55. The firm has a market capitalization of $9.20 billion, a P/E ratio of 22.05, a P/E/G ratio of 1.30 and a beta of 0.89.

Encompass Health (NYSE:EHC) last announced its quarterly earnings data on Monday, October 28th. The company reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.09. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.33 billion. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. The company’s revenue was up 11.9% on a year-over-year basis. During the same period last year, the business earned $0.86 EPS. As a group, sell-side analysts expect that Encompass Health Co. will post 4.29 EPS for the current year.

Encompass Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Thursday, January 2nd will be issued a $0.17 dividend. This represents a $0.68 annualized dividend and a dividend yield of 0.74%. The ex-dividend date of this dividend is Thursday, January 2nd. Encompass Health’s payout ratio is currently 16.43%.

Analysts Set New Price Targets

A number of research firms have recently weighed in on EHC. Royal Bank of Canada increased their price target on Encompass Health from $105.00 to $110.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Truist Financial reaffirmed a “buy” rating and set a $116.00 target price (up previously from $108.00) on shares of Encompass Health in a research note on Wednesday, October 30th. Barclays upped their price objective on shares of Encompass Health from $109.00 to $116.00 and gave the stock an “overweight” rating in a report on Tuesday, October 29th. UBS Group boosted their target price on Encompass Health from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Finally, KeyCorp raised their price target on Encompass Health from $115.00 to $117.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 29th. Nine research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Encompass Health currently has a consensus rating of “Buy” and an average target price of $107.11.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.